Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges

Trends in Biotechnology

Volumn 35, Issue 7, 2017, Pages 665-676

  Syn, Nicholas L ^a,b   Wang, Lingzhi ^a,c   Chow, Edward Kai Hua ^a,c   Lim, Chwee Teck ^d,e,f   Goh, Boon Cher ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Singapore   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer nanomedicine; cancer vaccines; drug delivery; exosomes; extracellular vesicles; immunotherapy

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; ONCOLOGY; TARGETED DRUG DELIVERY; VACCINES;

BIOLOGICAL BARRIER; CANCER IMMUNOTHERAPY; CANCER VACCINE; CLINICAL DEVELOPMENT; EXOSOMES; EXTRACELLULAR; IMMUNOTHERAPY; STATE-OF-THE-ART TECHNOLOGY;

DISEASES;

CANCER VACCINE; CYTOTOXIC AGENT; NUCLEIC ACID; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL FREE SYSTEM; CELL MATURATION; DENDRITIC CELL; DRUG TARGETING; EXOSOME; HUMAN; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ANIMAL; DRUG DELIVERY SYSTEM; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES;

ANIMALS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; EXOSOMES; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 85016647301     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2017.03.004     Document Type: Review

References (86)

1. Zitvogel, L., et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 4 (1998), 594–600.
2. Wolfers, J., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7 (2001), 297–303.
3. Syn, N., et al. Exosome-mediated metastasis: from epithelial – mesenchymal transition to escape from immunosurveillance. Trends Pharmacol. Sci. 37 (2016), 606–616.
4. Hoshino, A., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
5. Toffoli, G., et al. Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin. Nanomedicine 10 (2015), 2963–2971.
6. Hadla, M., et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models. Nanomedicine 11 (2016), 2431–2441.
7. Tian, Y., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35 (2014), 2383–2390.
8. Srivastava, A., et al. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci. Rep., 6, 2016, 38541.
9. Aqil, F., et al. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp. Mol. Pathol. 101 (2016), 12–21.
10. Kim, M.S., et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine Nanotechnology, Biol. Med. 12 (2016), 655–664.
11. Saari, H., et al. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J. Control. Release 220 (2015), 727–737.
12. Pascucci, L., et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J. Control. Release 192 (2014), 262–270.
13. Yang, T., et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 32 (2015), 2003–2014.
14. Martins-Marques, T., Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin. J. Extracell. Vesicles, 5, 2016, 32538.
15. Yang, Y., et al. Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress. Int. J. Hyperth. 31 (2015), 498–506.
16. Mulcahy, L.A., et al. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles, 3, 2014, 24641.
17. Tian, T., et al. Dynamics of exosome internalization and trafficking. J. Cell. Physiol. 228 (2013), 1487–1495.
18. Heusermann, W., et al. Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. J. Cell Biol. 213 (2016), 173–184.
19. Rivoltini, L., et al. TNF-related apoptosis-inducing ligand (TRAIL)-armed exosomes deliver proapoptotic signals to tumor site. Clin. Cancer Res. 22 (2016), 3499–3512.
20. Shimbo, K., et al. Exosome-formed synthetic microRNA-143 is transferred to osteosarcoma cells and inhibits their migration. Biochem. Biophys. Res. Commun. 445 (2014), 381–387.
21. Ohno, S., et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21 (2013), 185–191.
22. Li, L., et al. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology 24 (2016), 38–44.
23. Erkan, E.P., et al. Extracellular vesicle-mediated suicide mRNA/protein delivery inhibits glioblastoma tumor growth in vivo. Cancer Gene Ther. 24 (2016), 38–44.
24. Mizrak, A., et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol. Ther. 21 (2013), 101–108.
25. Stewart, M.P., et al. In vitro and ex vivo strategies for intracellular delivery. Nature 538 (2016), 183–192.
26. Melo, S.A., et al. Cancer exosomes perform cell-independent MicroRNA biogenesis and promote tumorigenesis. Cancer Cell 26 (2014), 707–721.
27. Zhou, W., et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25 (2014), 501–515.
28. Aga, M., et al. Exosomal HIF1α supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 33 (2014), 4613–4622.
29. Qu, L., et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell 29 (2016), 653–668.
30. Zhang, L., et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527 (2015), 100–104.
31. Lamichhane, T.N., et al. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell. Mol. Bioeng. 9 (2016), 315–324.
32. Syn, N.L.-X., et al. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin. Drug Metab. Toxicol. 12 (2016), 911–922.
33. Pitt, J.M., et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126 (2016), 1224–1232.
34. Lugini, L., et al. Immune surveillance properties of human NK cell-derived exosomes. J. Immunol. 189 (2012), 2833–2842.
35. Mahaweni, N.M., et al. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell. Vesicles, 2, 2013, 22492.
36. Koyama, Y., et al. Exosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy. Biotechnol. Lett. 38 (2016), 1857–1866.
37. Gu, X., et al. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 136 (2015), E74–E84.
38. Daßler-Plenker, J., RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology, 5, 2016, e1219827.
39. Munich, S., et al. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1 (2012), 1074–1083.
40. Viaud, S., et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One, 4, 2009, e4942.
41. Viaud, S., et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of Interferon-γ. J. Immunother. 34 (2011), 65–75.
42. Naslund, T.I., et al. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity. J. Immunol. 190 (2013), 2712–2719.
43. Gehrmann, U., et al. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res. 73 (2013), 3865–3876.
44. Damo, M., et al. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci. Rep., 5, 2015, 17622.
45. Romagnoli, G.G., et al. Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets. Front. Immunol., 5, 2014, 692.
46. Munich, S., et al. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1 (2012), 1074–1083.
47. Escudier, B., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med., 3, 2005, 10.
48. Morse, M.A., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med., 3, 2005, 9.
49. Besse, B., et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology, 5, 2016, e1071008.
50. Syn, N., et al. The National University Cancer Institute, Singapore (NCIS) Integrated Molecular Analysis of Cancer (IMAC) precision oncology programme: frequency of actionable mutations and outcomes following matched therapy in an Asian Cancer Centre. Ann. Oncol., 27, 2016 mdw579.001.
51. Stockley, T.L., et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med., 8, 2016, 109.
52. Schwaederle, M., et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms. JAMA Oncol., 2, 2016, 1452.
53. Chauhan, S., et al. Surface glycoproteins of exosomes shed by myeloid-derived suppressor cells contribute to function. J. Proteome Res. 16 (2016), 238–246.
54. Haraszti, R.A., et al. High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J. Extracell. Vesicles, 5, 2016, 32570.
55. Smyth, T.J., et al. Examination of the specificity of tumor cell derived exosomes with tumor cells in vitro. Biochim. Biophys. Acta 1838 (2014), 2954–2965.
56. Smyth, T., et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Release 199 (2015), 145–155.
57. Wiklander, O.P.B., Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles, 4, 2015, 26316.
58. Smith, Z.J., et al. Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content. J. Extracell. Vesicles, 4, 2015, 28533.
59. El-Andaloussi, S., Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7 (2012), 2112–2126.
60. Kooijmans, S.A.A., Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J. Extracell. Vesicles, 5, 2016, 31053.
61. Watson, D.C., et al. Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials 105 (2016), 195–205.
62. Kooijmans, S.A.A., PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J. Control. Release 224 (2016), 77–85.
63. Qi, H., et al. Blood exosomes endowed with magnetic and targeting properties for cancer therapy. ACS Nano 10 (2016), 3323–3333.
64. Kooijmans, S.A.A., Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J. Control. Release 172 (2013), 229–238.
65. Lamichhane, T.N., et al. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery. Mol. Pharm. 12 (2015), 3650–3657.
66. Johnsen, K.B., et al. Evaluation of electroporation-induced adverse effects on adipose-derived stem cell exosomes. Cytotechnology 68 (2016), 2125–2138.
67. Lee, J., et al. Liposome-based engineering of cells to package hydrophobic compounds in membrane vesicles for tumor penetration. Nano Lett. 15 (2015), 2938–2944.
68. Yim, N., et al. Exosome engineering for efficient intracellular delivery of soluble proteins using optically reversible protein–protein interaction module. Nat. Commun., 7, 2016, 12277.
69. Janas, T., et al. Mechanisms of RNA loading into exosomes. FEBS Lett. 589 (2015), 1391–1398.
70. Villarroya-Beltri, C., Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat. Commun., 4, 2013, 2980.
71. Hiltbrunner, S., et al. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget 7 (2016), 38707–38717.
72. Näslund, T.I., et al. Cancer immunotherapy with exosomes requires B-cell activation. Oncoimmunology, 2, 2013, e24533.
73. Hiltbrunner, S., et al. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget 7 (2016), 38707–38717.
74. Gehrmann, U., et al. Potentiating antitumor immunity with αGC-loaded exosomes. Oncoimmunology, 2, 2013, e26261.
75. Hao, S., et al. Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity. Cancer Biother. Radiopharm. 21 (2006), 146–154.
76. Srinivasan, S., et al. Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep., 6, 2016, 24436.
77. Lener, T., et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J. Extracell. Vesicles, 4, 2015, 30087.
78. Wilhelm, S., et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater., 1, 2016, 16014.
79. Yeo, R.W.Y., et al. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65 (2013), 336–341.
80. Lobb, R.J., et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J. Extracell. Vesicles, 4, 2015, 27031.
81. Royo, F., et al. Different EV enrichment methods suitable for clinical settings yield different subpopulations of urinary extracellular vesicles from human samples. J. Extracell. Vesicles, 5, 2016, 29497.
82. Wunsch, B.H., et al. Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nm. Nat. Nanotechnol. 11 (2016), 936–940.
83. Yeo, J.C., et al. Microfluidic size separation of cells and particles using a swinging bucket centrifuge. Biomicrofluidics, 9, 2015, 54114.
84. Wang, Z., et al. Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles. Lab Chip, 13, 2013, 2879.
85. Lee, K., et al. Acoustic purification of extracellular microvesicles. ACS Nano 9 (2015), 2321–2327.
86. Yuana, Y., et al. Handling and storage of human body fluids for analysis of extracellular vesicles. J. Extracell. Vesicles, 4, 2015, 29260.